Andrew Reaume
Vorstandsvorsitzender bei Melior Discovery, Inc.
Profil
Andrew Reaume is the founder of Melior Discovery, Inc. (founded in 2005) where he holds the title of President & Chief Executive Officer.
He is also the founder of Melior Pharmaceuticals I, Inc. (founded in 2008) where he holds the title of President.
Additionally, he is the founder of Melior Pharmaceuticals II LLC (founded in 2008) where he holds the title of President & Chief Executive Officer.
Dr. Reaume's former job(s) include being a Director at Adhera Therapeutics, Inc., a Research Scientist at Cephalon, Inc. (from 1993 to 1999), and a Senior Business Analyst at Pfizer Inc.Dr. Reaume's education history includes an MBA from the University of Pennsylvania (conferred in 2003) and a doctorate from the University of Connecticut (conferred in 1990).
Aktive Positionen von Andrew Reaume
| Unternehmen | Position | Beginn |
|---|---|---|
Melior Discovery, Inc.
 Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Vorstandsvorsitzender | 01.01.2005 |
Melior Pharmaceuticals I, Inc.
 Melior Pharmaceuticals I, Inc. Pharmaceuticals: MajorHealth Technology Melior Pharmaceuticals I, Inc. is a mid-stage biopharmaceutical company that develops therapies for diabetes, Parkinson's disease, sleep disorders, and nonalcoholic steatohepatitis (NASH). The private company is based in Exton, PA and was founded in 2008 by Andrew Reaume. The company's lead clinical stage candidates are in the areas of diabetes, NASH, Parkinson's disease, and sleep disorders. The company leverages the technology of their affiliate discovery for stage 1 research. Tolimidone is a Lyn kinase activator for treating type 2 diabetes and NASH. Mesocarb is a dopamine reuptake inhibitor for treating Parkinson's disease, sleep disorders, and other CNS conditions. | Gründer | 01.12.2008 |
Ehemalige bekannte Positionen von Andrew Reaume
| Unternehmen | Position | Ende |
|---|---|---|
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Corporate Officer/Principal | 01.01.1999 |
| ADHERA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Ausbildung von Andrew Reaume
| University of Pennsylvania | Masters Business Admin |
| University of Connecticut | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| ADHERA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
Melior Discovery, Inc.
Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Commercial Services |
Melior Pharmaceuticals I, Inc.
Melior Pharmaceuticals I, Inc. Pharmaceuticals: MajorHealth Technology Melior Pharmaceuticals I, Inc. is a mid-stage biopharmaceutical company that develops therapies for diabetes, Parkinson's disease, sleep disorders, and nonalcoholic steatohepatitis (NASH). The private company is based in Exton, PA and was founded in 2008 by Andrew Reaume. The company's lead clinical stage candidates are in the areas of diabetes, NASH, Parkinson's disease, and sleep disorders. The company leverages the technology of their affiliate discovery for stage 1 research. Tolimidone is a Lyn kinase activator for treating type 2 diabetes and NASH. Mesocarb is a dopamine reuptake inhibitor for treating Parkinson's disease, sleep disorders, and other CNS conditions. | Health Technology |
